MX2022007029A - Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped. - Google Patents
Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped.Info
- Publication number
- MX2022007029A MX2022007029A MX2022007029A MX2022007029A MX2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A MX 2022007029 A MX2022007029 A MX 2022007029A
- Authority
- MX
- Mexico
- Prior art keywords
- host disease
- antibodies
- treatment
- chronic graft
- versus host
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945842P | 2019-12-09 | 2019-12-09 | |
| US202063110111P | 2020-11-05 | 2020-11-05 | |
| PCT/US2020/064010 WO2021119128A1 (en) | 2019-12-09 | 2020-12-09 | Antibodies for the treatment of chronic graft versus host disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007029A true MX2022007029A (es) | 2022-08-15 |
Family
ID=76330540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007029A MX2022007029A (es) | 2019-12-09 | 2020-12-09 | Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12552869B2 (https=) |
| EP (1) | EP4073100A4 (https=) |
| JP (1) | JP2023506779A (https=) |
| KR (1) | KR20220123004A (https=) |
| CN (1) | CN115298210A (https=) |
| AU (1) | AU2020401551A1 (https=) |
| CA (1) | CA3164126A1 (https=) |
| IL (1) | IL293705A (https=) |
| MX (1) | MX2022007029A (https=) |
| PH (1) | PH12022551401A1 (https=) |
| WO (1) | WO2021119128A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260013464A (ko) * | 2023-05-17 | 2026-01-28 | 신닥스 파마슈티컬스, 인크. | 항-콜로니 자극 인자 1 수용체 항체를 이용한 만성 이식편대숙주 질환-관련 폐쇄성 세기관지염 증후군의 치료 방법 |
| CN121620392A (zh) * | 2023-07-23 | 2026-03-06 | 因赛特公司 | 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病的方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| JP2008526773A (ja) * | 2004-12-30 | 2008-07-24 | ドール バイオファーマ、インコーポレイテッド | ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療 |
| WO2007142667A2 (en) | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
| EP2076266A2 (en) | 2006-05-31 | 2009-07-08 | The Board of Trustees of the Leland Stanford Junior University | Method of treating inflammatory diseases using tyroskine kinase inhibitors |
| WO2008055013A2 (en) | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase |
| PL2188313T3 (pl) | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US20090148905A1 (en) | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| BRPI0909044B8 (pt) | 2008-03-14 | 2021-05-25 | Transgene Sa | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos |
| WO2010012667A1 (en) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Micro-rna mediated modulation of colony stimulating factors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| WO2013057281A2 (en) | 2011-10-21 | 2013-04-25 | Transgene Sa | Modulation of macrophage activation |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| ES2763309T3 (es) | 2015-02-09 | 2020-05-28 | UCB Biopharma SRL | Formulación farmacéutica que comprende anticuerpos |
| CN111278459A (zh) * | 2017-05-19 | 2020-06-12 | 赛达克斯制药股份有限公司 | 组合疗法 |
-
2020
- 2020-12-09 EP EP20899869.0A patent/EP4073100A4/en active Pending
- 2020-12-09 CA CA3164126A patent/CA3164126A1/en active Pending
- 2020-12-09 KR KR1020227023446A patent/KR20220123004A/ko active Pending
- 2020-12-09 CN CN202080095646.6A patent/CN115298210A/zh active Pending
- 2020-12-09 US US17/783,552 patent/US12552869B2/en active Active
- 2020-12-09 AU AU2020401551A patent/AU2020401551A1/en active Pending
- 2020-12-09 PH PH1/2022/551401A patent/PH12022551401A1/en unknown
- 2020-12-09 MX MX2022007029A patent/MX2022007029A/es unknown
- 2020-12-09 JP JP2022535607A patent/JP2023506779A/ja active Pending
- 2020-12-09 WO PCT/US2020/064010 patent/WO2021119128A1/en not_active Ceased
- 2020-12-09 IL IL293705A patent/IL293705A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4073100A1 (en) | 2022-10-19 |
| KR20220123004A (ko) | 2022-09-05 |
| US12552869B2 (en) | 2026-02-17 |
| PH12022551401A1 (en) | 2023-08-23 |
| IL293705A (en) | 2022-08-01 |
| WO2021119128A1 (en) | 2021-06-17 |
| CA3164126A1 (en) | 2021-06-17 |
| JP2023506779A (ja) | 2023-02-20 |
| AU2020401551A1 (en) | 2022-06-30 |
| EP4073100A4 (en) | 2024-02-14 |
| CN115298210A (zh) | 2022-11-04 |
| US20230035183A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2024000220A (es) | Anticuerpos il-11 | |
| EA201990548A1 (ru) | Лечение кластерной головной боли | |
| EA202092605A1 (ru) | Антитела к ил-11ra | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| MX2016014210A (es) | Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes. | |
| MX2018014560A (es) | Metodos para el tratamiento de la miastenia gravis generalizada refractaria. | |
| CL2016001979A1 (es) | Métodos de tratamiento de enfermedad de alzheimer. | |
| MX2021010893A (es) | Anticuerpo biespecifico enlazado especificamente a vegf y ang2. | |
| CL2023001052A1 (es) | Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea | |
| EA202191352A1 (ru) | Контроль содержания микроэлементов-металлов во время продукции антител к cd38 | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| EA201691020A1 (ru) | Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина" | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| CL2021000146A1 (es) | Anticuerpos humanizados contra psma | |
| EA201892525A1 (ru) | Конструкции днк-антител для применения против pseudomonas aeruginosa | |
| AU2017310412A8 (en) | Method of improving connective tissue attachment using anti-sclerostin antibodies | |
| MX2022007029A (es) | Anticuerpos para el tratamiento de la enfermedad cronica de injerto versus huesped. | |
| EA201992315A1 (ru) | Композиции и способы для лечения рака легкого | |
| PH12021550991A1 (en) | Monoclonal antibody that specifically binds to cd20 | |
| BR112021018611A2 (pt) | Anticorpos tendo especificidade para btn2 e usos dos mesmos | |
| EA202190504A1 (ru) | Способы лечения псориаза |